Skip to content
Screener

Medtronic MDT Diabetes — Reportable segment operating profit

Other segment segments

Cardiovascular
$1.07B+11.8%
Neuroscience
$879M+2.4%
Medical Surgical
$605M+5.2%
Other operating segment
-$1M-108%

Similar metrics at other companies

California Resources logo
CRCTotal Reportable Segments — Segment profit or (loss)
$270M+12.0%
ARE
AREReportable Segment, Aggregation before Other Operating Segment — Reportable segment net operating income (reportable segment profit or loss)
$413.14M-16.2%
Elevance Health logo
ELVCarelonRx Segment — Reportable segments’ operating gain
$582M+8.6%
Designer Brands logo
DBIRetail — Segment operating profit
$51.28M+28.3%
United Parcel Service, Inc. logo
UPSInternational Segment — Operating profit
$623M-7.3%
LCI Industries logo
LCIIAftermarket Segment — Operating profit
$51.88M+43.6%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$110.07B-3.9%
Enterprise value$137.33B-3.2%
P/E22.9×-1.6×
P/S3×-0.3×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Medtronic’s 10-Q, filed February 24, 2026.

Filed
Feb 24, 2026, 4:18 PM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-011107
(in millions)CardiovascularNeuroscienceMedical SurgicalDiabetesTotal
Research and development expense284153174109720
Selling, general, and administrative expense1,1298416283002,897
Other segment items(2)(14)126(2)3
Reportable segment operating profit$899$737$499$57$2,192
Reconciliation of segment profit / (loss)
Other operating segment profit (loss)(1)(1)
Currency and other(13)
Interest expense, net(181)

Item 1. Financial Statements

FAQ

What is Medtronic's diabetes — reportable segment operating profit?
Medtronic (MDT) reported diabetes — reportable segment operating profit of $57M in Q4 2025.
How has Medtronic's diabetes — reportable segment operating profit changed year-over-year?
Medtronic's diabetes — reportable segment operating profit increased by 14.0% year-over-year, from $50M to $57M.
What is the long-term trend for Medtronic's diabetes — reportable segment operating profit?
Over 3 years (2022 to 2025), Medtronic's diabetes — reportable segment operating profit has grown at a -5.9% compound annual growth rate (CAGR), from $589M to $490M.
What does diabetes — reportable segment operating profit mean?
This measures the profitability of the diabetes segment after deducting operating expenses like R&D, SG&A, and production costs from net sales. It excludes corporate-level allocations, interest, and taxes, providing a clear view of the segment's operational efficiency. It is the key metric for evaluating the segment's contribution to the company's overall bottom line.

Ask your AI about Medtronic's diabetes — reportable segment operating profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude